An extended fatty liver index to predict non-alcoholic fatty liver disease

Diabetes and Metabolism

Volumn 43, Issue 3, 2017, Pages 229-239

  Kantartzis, K ^a,b   Rettig, I ^a   Staiger, H ^a,b   Machann, J ^a,b   Schick, F ^a,b   Scheja, L ^c   Gastaldelli, A ^d   Bugianesi, E ^e   Peter, A ^a,b   Schulze, M B ^b,f   Fritsche, A ^a,b   Haring H U ^a,b   Stefan, N ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

Fatty liver; Lifestyle intervention; NAFLD; OGTT; Prediction; Triglycerides

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AEROBIC EXERCISE; ANTHROPOMETRY; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; ENDURANCE TRAINING; EXTENDED FATTY LIVER INDEX; FEMALE; GENE; GLUCOSE BLOOD LEVEL; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; NUTRITIONAL COUNSELING; ORAL GLUCOSE TOLERANCE TEST; PNPLA3 GENE; PREDICTIVE VALUE; PROTON NUCLEAR MAGNETIC RESONANCE; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; COHORT ANALYSIS; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; ROC CURVE; TRIGLYCERIDES;

EID: 85009812505     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2016.11.006     Document Type: Article

References (43)

1. Williams, C.D., Stengel, J., Asike, M.I., Torres, D.M., Shaw, J., Contreras, M., et al. Harrison SA: prevalence of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
2. Gastaldelli, A., Kozakova, M., Højlund, K., Flyvbjerg, A., Favuzzi, A., Mitrakou, A., et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 49 (2009), 1537–1544.
3. Byrne, C.D., Targher, G., NAFLD: a multisystem disease. J Hepatol 62 (2015), S47–S64.
4. Anstee, Q.M., Targher, G., Day, C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10 (2013), 330–344.
5. Cohen, J.C., Horton, J.D., Hobbs, H.H., Human fatty liver disease: old questions and new insights. Science 332 (2011), 1519–1523.
6. Cusi, K., Role of obesity and lipotoxicity in the development of non-alcoholic steatohepatitis:pathophysiology and clinical implications. Gastroenterology 142 (2012), 711–725.
7. Stefan, N., Häring, H.U., The role of hepatokines in metabolism. Nat Rev Endocrinol 9 (2013), 144–152.
8. Stefan, N., Häring, H.U., Circulating fetuin-A and free fatty acids interact to predict insulin resistance in humans. Nat Med 19 (2013), 394–395.
9. Targher, G., Day, C.P., Bonora, E., Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363 (2010), 341–350.
10. Armstrong, M., Adams, L.A., Canbay, A., Syn, W.K., Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59 (2014), 1174–1197.
11. Polyzos, S.A., Kountouras, J., Mantzoros, C.S., Adipokines in nonalcoholic fatty liver disease. Metabolism 65 (2016), 1062–1079.
12. Stefan, N., Fritsche, A., Schick, F., Häring, H.U., Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol 4 (2016), 789–798.
13. Bravo, A.A., Sheth, S.G., Chopra, S., Liver biopsy. N Engl J Med 344 (2001), 495–500.
14. Machado, M.V., Cortez-Pinto, H., Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 58 (2013), 1007–1019.
15. Szczepaniak, L.S., Nurenberg, P., Leonard, D., Browning, J.D., Reingold, J.S., Grundy, S., et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288 (2005), E462–E468.
16. Machann, J., Thamer, C., Stefan, N., Schwenzer, N.F., Kantartzis, K., Häring, H.U., et al. Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology 257 (2010), 353–363.
17. Dasarathy, S., Dasarathy, J., Khiyami, A., Joseph, R., Lopez, R., McCullough, A.J., Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 51 (2009), 1061–1067.
18. Poynard, T., Ratziu, V., Naveau, S., Thabut, D., Charlotte, F., Messous, D., et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol, 4, 2005, 10.
19. Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol, 6, 2006, 33.
20. Kotronen, A., Peltonen, M., Hakkarainen, A., Sevastianova, K., Bergholm, R., Johansson, L.M., et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 137 (2009), 865–872.
21. Lee, J.H., Kim, D., Kim, H.J., Lee, C.H., Yang, J.I., Kim, W., et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42 (2010), 503–508.
22. Centis, E., Marzocchi, R., Di Domizio, S., Ciaravella, M.F., Marchesini, G., The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis 28 (2010), 267–273.
23. Kantartzis, K., Thamer, C., Peter, A., Machann, J., Schick, F., Schraml, C., et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58 (2009), 1281–1288.
24. Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 (2008), 1461–1465.
25. Vossen, M., Tödter, K., Altenburg, C., Beisiegel, U., Scheja, L., Plasma triglycerides after oral glucose load specifically associate with metabolic risk markers in healthy type 2 diabetes offspring. Atherosclerosis 217 (2011), 214–219.
26. Stefan, N., Staiger, H., Wagner, R., Machann, J., Schick, F., Häring, H.U., et al. A high-risk phenotype associates with reduced improvement in glycaemia during a lifestyle intervention in prediabetes. Diabetologia 58 (2015), 2877–2884.
27. Stefan, N., Ramsauer, M., Jordan, P., Nowotny, B., Kantartzis, K., Machann, J., et al. Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre randomised double-blind placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 406–416.
28. Thomas, E.L., Hamilton, G., Patel, N., O'Dwyer, R., Doré, C.J., Goldin, R.D., et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 54 (2005), 122–127.
29. Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004), 1387–1395.
30. Matsuda, M., DeFronzo, R.A., Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22 (1999), 1462–1470.
31. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F., Turner, R.C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
32. Kantartzis, K., Peter, A., Machicao, F., Machann, J., Wagner, S., Königsrainer, I., et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58 (2009), 2616–2623.
33. Chalasani, N., Nonalcoholic fatty liver disease liver fat score and fat equation to predict and quantitate hepatic steatosis: promising but not prime time!. Gastroenterology 137 (2009), 772–775.
34. Calori, G., Lattuada, G., Ragogna, F., Garancini, M.P., Crosignani, P., Villa, M., et al. Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 54 (2011), 145–152.
35. Bozkurt, L., Göbl, C.S., Tura, A., Chmelik, M., Prikoszovich, T., Kosi, L., et al. Fatty liver index predicts further metabolic deteriorations in women with previous gestational diabetes. PLoS One, 7, 2012, e32710.
36. Fedchuk, L., Nascimbeni, F., Pais, R., Charlotte, F., Housset, C., Ratziu, V., et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 40 (2014), 1209–1222.
37. Kahl, S., Straßburger, K., Nowotny, B., Livingstone, R., Klüppelholz, B., Keßel, K., et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One, 9, 2014, e94059.
38. Adiels, M., Taskinen, M.R., Packard, C., Caslake, M.J., Soro-Paavonen, A., Westerbacka, J., et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 49 (2006), 755–765.
39. Jeppesen, J., Hollenbeck, C.B., Zhou, M.Y., Coulston, A.M., Jones, C., Chen, Y.D., et al. Relation between insulin resistance hyperinsulinemia postheparin plasma lipoprotein lipase activity and postprandial lipemia. Arterioscler Thromb Vasc Biol 15 (1995), 320–324.
40. Laatsch, A., Merkel, M., Talmud, P.J., Grewal, T., Beisiegel, U., Heeren, J., Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. Atherosclerosis 204 (2009), 105–111.
41. Sidossis, L.S., Mittendorfer, B., Walser, E., Chinkes, D., Wolfe, R.R., Hyperglycemia-induced inhibition of splanchnic fatty acid oxidation increases hepatic triacylglycerol secretion. Am J Physiol 275 (1998), E798–E805.
42. 1H-MR spectroscopy. Eur Radiol 22 (2012), 855–863.
43. Rosso, C., Mezzabotta, L., Gaggini, M., Salomone, F., Gambino, R., Marengo, A., et al. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology 63 (2016), 107–116.